Immediate evolocumab after a heart attack improves LDL-cholesterol goals but not early cardiovascular outcomes
Immediate in-hospital administration of the PCSK9 inhibitor evolocumab following a heart attack significantly improves low-density lipoprotein cholesterol goal attainment at one…